Merck KGaA (OTCMKTS:MKGAF) Reaches New 12-Month High at $133.00

Merck KGaA (OTCMKTS:MKGAF) reached a new 52-week high during trading on Wednesday . The company traded as high as $133.00 and last traded at $133.00, with a volume of 83 shares traded. The stock had previously closed at $131.85.

Separately, ValuEngine lowered Merck KGaA from a “hold” rating to a “sell” rating in a research report on Friday, January 10th.

The firm has a market capitalization of $17.32 billion, a P/E ratio of 15.65 and a beta of 0.71. The stock has a 50-day moving average of $126.35 and a 200 day moving average of $115.97.

About Merck KGaA (OTCMKTS:MKGAF)

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: How to Invest in an Index Fund

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.